UCLA Department of Bioengineering

The most exciting science in the 21st century is likely to evolve among, not within, traditional disciplines. Around the world, Bioengineering has begun to establish itself as an independent field and engineering discipline, at the boundary between biology and the physical sciences. UCLA and the faculty of bioengineering have embraced this critical and unique opportunity to make a rapid significant impact in the field with an innovative curriculum, state-of-the-art facilities, and cutting-edge research.

Related News

NORTHWEST BIOTHERAPEUTICS ANNOUNCES THE COMPLETION OF FINANCING ON A FAVORABLE TERMS FOR APPROXIMATELY $8 MILLION

Northwest Biotherapeutics | August 12, 2020

news image

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...

Read More

MEDICAL

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

news image

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More

CELL AND GENE THERAPY

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

news image

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More

INDUSTRIAL IMPACT

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

news image

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More
news image

NORTHWEST BIOTHERAPEUTICS ANNOUNCES THE COMPLETION OF FINANCING ON A FAVORABLE TERMS FOR APPROXIMATELY $8 MILLION

Northwest Biotherapeutics | August 12, 2020

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...

Read More
news image

MEDICAL

INVENSHURE LAUNCHES MEKANISTIC THERAPEUTICS™

Invenshure | June 03, 2022

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity...

Read More
news image

CELL AND GENE THERAPY

INNOVENT ANNOUNCES FIRST PATIENT DOSING OF UNIVERSAL MODULAR CAR-T CELL PRODUCT IBI345

Innovent Biologics | February 21, 2022

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its first-in-class IgG-based universal "modular" Claudin 18.2-targeting chimeric antigen receptor T (CAR-T) cell product (development code: IBI345) for the treatment of advanced Claudin18.2-positive solid tumors in an investigator-...

Read More
news image

INDUSTRIAL IMPACT

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More